Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432673 | 0.93 | CYP19A1 (0.56) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL2604717 | 0.91 | CYP19A1 (0.64) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL2070571 | 0.89 | CYP19A1 (0.61) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL19410272 | 0.87 | CYP19A1 (0.62) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL19410273 | 0.84 | CYP19A1 (0.55) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL3957591 | 0.83 | ALOX12 (0.53) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL3956230 | 0.83 | ALOX12 (0.46) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL6143062 | 0.81 | CYP19A1 (0.63) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL5503331 | 0.81 | CYP19A1 (0.84) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL12055312 | 0.80 | ALOX12 (0.44) | CYP19A1ALOX12ALOX15KCNH2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | claimed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | claimed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | claimed |
| EP-3191464-B1 | SYNTHESIS OF ISOFLAVANES AND INTERMEDIATES THEREOF | SYSTEM BIOLOGIE AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | SYSTEM BIOLOGIE AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | SYSTEM BIOLOGIE AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | SYSTEM BIOLOGIE AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | SYSTEM BIOLOGIE AG (CH) | 2017-10-05 | — | — | US | disclosed |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| EP-2436680-B1 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1809618-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty Ltd (AU) | 2007-07-25 | — | — | EP | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032086-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP19A1 5/4885ALOX12 2451/4885ALOX15 2360/4885 |
| US-10030003-B2 | Synthesis of isoflavanes and intermediates thereof | CYP4B1, CYP51A1, CYP4A11 | CYP19A1 5/4885ALOX12 1662/4885ALOX15 1439/4885 |
| US-20170283389-A1 | Synthesis of Isoflavanes and Intermediates Thereof | CYP4B1, CYP51A1, CYP4A11 | CYP19A1 5/4885ALOX12 1662/4885ALOX15 1439/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | CYP19A1 5/4885ALOX12 2451/4885ALOX15 2360/4885 |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | CYP19A1 2946/4885ALOX12 3724/4885ALOX15 3665/4885 |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | CDYL, XPA, TP53 | CYP19A1 2946/4885ALOX12 3724/4885ALOX15 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.